Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
CEOs Vs. Hedge Fund Managers: Who Gets Paid Better?
Has A Biotech Recovery Started Yet?
Related AGN
JPMorgan: Monsanto Shares Could Hit $180 Over The Next 5 Years
Allergan Says FDA Accepts Its NDA Filing Of Oxymetazoline HCI Cream 1.0%
Buy Into Teva's Uncertainty? (Seeking Alpha)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Apr 2016Wells FargoDowngradesOutperformMarket Perform
Apr 2016Leerink SwannMaintainsOutperform
Apr 2016Roth CapitalMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

View Comments and Join the Discussion!